Amgen (Nasdaq: AMGN) stock remains in focus after Q1 2026 Earnings beat estimates, raised full-year guidance and expanded MariTide Phase 3 obesity and diabetes studies amid intensifying GLP-1 competition.

Key Highlights

  • Amgen raised 2026 Revenue and EPS guidance after stronger-than-expected Q1 earnings.
  • MariTide Phase 3 obesity and diabetes programs expanded across multiple late-stage studies.
  • Investors remain focused on GLP-1 competition, biosimilar risks and long-term pipeline execution.

Amgen Inc. (NASDAQ: AMGN) is one of the most-watched US large-cap biotech stocks as the company advances its MariTide obesity and metabolic disease Franchise. With a market Capitalization of about $176.11 billion, AMGN continues to anchor the diversified biotech sector. Shares fell 2.95%.

Why the Stock Is in Focus Today

Amgen reported Q1 2026 results on April 30 with total revenue of $8.6 billion (up 6% year over year) and non-GAAP EPS of $5.15 (up 5%, beating $4.80 consensus). Six growth drivers powered approximately 24% expansion. The company raised full-year 2026 guidance to revenue of $37.1-$38.5 billion and non-GAAP EPS of $21.70-$23.10. The MariTide obesity and metabolic franchise advanced with the initiation of the Phase 3 MARITIME-SWITCH study (evaluating switching from weekly injectable GLP-1 therapies to MariTide at every-eight-week or quarterly dosing) and two Phase 3 MARITIME chronic weight management maintenance extension studies. Three Phase 3 type-2 diabetes studies are planned for 2026.

Latest Share Price Movement

AMGN traded at $326.31, down 2.95% on the day, with Volume of 3.45 million shares and a relative volume reading of 1.21. The stock saw a roughly 2.4% post-earnings decline.

Key News Driving Investor Attention

Three news items dominate. First, the Q1 beat and raised 2026 guidance. Second, the MariTide Phase 3 program expansion targeting obesity and type-2 diabetes. Third, six growth drivers cited by management on the call.

Earnings and Financial Performance

Diluted EPS on a trailing-twelve-month basis stands at $14.38 with EPS growth of +31.26% year over year. The portfolio Diversification is supporting consistent earnings expansion.

Analyst and Market Sentiment

Analyst sentiment on AMGN is moderately positive. Bulls highlight MariTide optionality; bears watch the long-term GLP-1 competitive landscape dominated by Eli Lilly (LLY) and Novo Nordisk.

Sector Outlook

AMGN competes in biotech with Eli Lilly, Novo Nordisk, Gilead (GILD) and Regeneron. The obesity GLP-1/GIP market is the primary battleground.

Risks Investors Are Watching

Risks include MariTide clinical and commercial execution, biosimilar erosion of legacy Biologics, IRA price negotiations and Capital allocation discipline.

What to Watch Next

Catalysts ahead include MariTide Phase 3 readouts, additional pipeline updates and Q2 2026 results.

Conclusion

Amgen remains one of the most closely monitored large-cap biotech companies as investors assess the long-term commercial potential of MariTide within the expanding obesity and metabolic disease market. Strong Q1 2026 earnings, raised full-year guidance and accelerating Phase 3 development activity reinforce management’s confidence in its next growth cycle. However, competitive pressure from established GLP-1 leaders, biosimilar erosion and regulatory risks continue to shape the broader valuation outlook. The next phase of investor focus will likely depend on late-stage MariTide clinical execution and the sustainability of Amgen’s diversified earnings growth.